Combination treatment for recurrent ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and a low-dose chemo) for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It aims to find a new option when standard platinum chemo no longer works or cannot be used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are able to be up and active (able to do light housework or office work).
- Your cancer is one of these types: serous, endometrioid, clear cell, mucinous, or undifferentiated ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer came back after treatment. It may have come back quickly (within 6 months of last platinum chemo, called platinum-resistant) or after 6+ months (platinum-sensitive) but only if you cannot have platinum chemo anymore.
- You have at least one tumor that can be seen on scans (like CT or MRI).
- You are willing to have a needle biopsy (small tissue sample) of your tumor before and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—liposomal irinotecan (a chemotherapy) and enlonstobart (an immune-boosting antibody)—for ovarian cancer that came back within 6 months of platinum-based chemotherapy. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests a combination of three drugs—liposomal irinotecan (chemotherapy), sintilimab (immunotherapy), and anlotinib (targeted therapy)—for people with recurrent or persistent ovarian clear cell carcinoma who have already tried platinum-based chemotherapy. The goal is to see if this triple therapy can shrink tumors or slow cancer growth.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.